Alnylam Pharmaceuticals Inc (FRA:DUL)
€ 137.65 3.7 (2.76%) Market Cap: 17.33 Bil Enterprise Value: 16.35 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 67/100

Alnylam Pharmaceuticals Inc to Present HELIOS-A 18-Month Results - Conference Call Transcript

Jan 21, 2022 / 01:30PM GMT
Release Date Price: €121.5 (-0.45%)
Operator

Ladies and gentlemen, thank you for standing by, and welcome to the Alnylam Pharmaceuticals conference call to discuss the 18-month results from the HELIOS-A Phase III study. There will be a question-and-answer session to follow. Please be advised that this call is being [recorded] at the company's request.

I would now like to turn the call over to the company.

Christine Regan Lindenboom
Alnylam Pharmaceuticals, Inc. - Senior VP of IR & Corporate Communications

Good morning. I'm Christine Lindenboom, Senior Vice President of Investor Relations and Corporate Communications at Alnylam. With me today on the phone are Yvonne Greenstreet, Chief Executive Officer; Akshay Vaishnaw, President; Pushkal Garg, Chief Medical Officer; and Rena Denoncourt, Vice President, TTR Franchise lease. Also, on the line and available for Q&A is John Vest, VP of Clinical Research.

For those of you participating via conference call, the accompanying slides can be accessed by going to the Events section of the Investors page of our website, alnylam.com/events.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot